File S1 - The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML

Data supplement. Text, NPM1 mutation type does not influence outcome - Subgroup analyses. A) NPM1 mutation type A versus rare type mutationsin 292 patients receiving chemotherapy only in 292 patients receiving chemotherapy only; in 330 patients with de novo AML; in patients NPM1 mutation types A versus B versus D versus other mutations in 292 patients receiving chemotherapy only. Table S1, Characteristics of NPM1-mutated patients and comparison between those with type A and rare type with or without a FLT3-ITD. Table S2, Frequency of different types of NPM1 mutations. Table S3, Univariable Cox regression for overall survival (OS) and relapse-free survival (RFS). Table S4, Multivariable Cox regression models for OS and RFS in 349 NPM1-mutated patients. Figure S1, Overview of patient Selection. Figure S2, Influence of a FLT3-ITD in 349 NPM1-mutated patients on outcome. (A) OS in 349 NPM1-mutated patients. (B) RFS in NPM1-mutated patients in CR. Figure S3, Overall Survival (OS) and Relapse-Free Survival (RFS) in 292 patients with cytogenetically normal acute myeloid leukemia and NPM1 mutation treated in the AMLCG99 study, not receiving allogeneic transplantation. (A) OS in patients with NPM1 type A mutation versus NPM1 rare type mutation. (B) OS in patients with NPM1 type A mutation versus NPM1 rare type mutation with or without an additional FLT3-ITD. (C) RFS in patients with NPM1 type A mutation versus NPM1 rare type mutation. (D) RFS in patients with NPM1 type A mutation versus NPM1 rare type mutation with or without an additional FLT3-ITD. Figure S4, Overall Survival (OS) and Relapse-Free Survival (RFS) in 330 patients with de novo cytogenetically normal acute myeloid leukemia and NPM1 mutation treated in the AMLCG99 study. (A) OS in patients with NPM1 type A mutation versus NPM1 rare type mutation. (B) OS in patients with NPM1 type A mutation versus NPM1 rare type mutation with or without an additional FLT3-ITD. (C) RFS in patients with NPM1 type A mutation versus NPM1 rare type mutation. (D) RFS in patients with NPM1 type A mutation versus NPM1 rare type mutation with or without an additional FLT3-ITD. Figure S5, Overall Survival (OS) and Relapse-Free Survival (RFS) in 197 patients NPM1 mutation treated in the AMLCG99 study. (A) OS in patients NPM1 type A mutation versus NPM1 rare type mutation. (B) OS in patients ≥60 years with NPM1 type A mutation versus NPM1 rare type mutation. (C) RFS in patients NPM1 type A mutation versus NPM1 rare type mutation. (D) RFS in patients ≥60 with NPM1 type A mutation versus NPM1 rare type mutation. (PDF)